|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.27 USD | -2.93% |
|
-8.19% | +10.30% |
| 22/05 | Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing | MT |
| 14/05 | Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM |
Vaxcyte, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 60.46 million compared to USD 38.99 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.68 a year ago.
Diluted loss per share from continuing operations was USD 0.7 compared to USD 0.68 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +10.30% | 7.54B | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -2.88% | 21.58B | |
| -10.93% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
VAXCYTE, INC. 
